Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp190 | Pituitary & endocrine Tumours | ECE2017

Safety of long-term growth hormone (GH) treatment in adults with GH deficiency (GHD): an analysis from the NordiNet® International Outcome Study

Jorgensen Jens Otto , Popovic-Brkic Vera , Pournara Effie , Pedersen Birgitte , Chudecka Anita , Strasburger Christian

Background: Long-term safety data (1998 to mid-2016) are reported for adult patients with GHD treated with GH (Norditropin® (somatropin), Novo Nordisk) as prescribed by treating physicians in the real-life clinical setting and enrolled in NordiNet® International Outcome Study (IOS) (NCT00960128), a non-interventional, multicentre study.Objective and hypotheses: To describe and report safety data and incidence rates (IRs) (...